Skip to main content
Top
Published in: Reviews in Endocrine and Metabolic Disorders 5/2022

22-08-2022 | Hyperparathyroidism

Cognitive deficits in primary hyperparathyroidism – what we know and what we do not know: A narrative review

Authors: Manju Chandran, Lydia Tan Li Yeh, Mechteld C. de Jong, John P. Bilezikian, Rajeev Parameswaran

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 5/2022

Login to get access

Abstract

Classic symptoms of primary hyperparathyroidism (PHPT) are seen in approximately 20% of patients. While features such as kidney stones and skeletal disease are often highlighted as directly related to the disease, others can be even more prevalent. For example, cognitive dysfunction and reduced quality of life are common complaints in many patients, even among those who are classified as being asymptomatic. The pathophysiology of PHPT involves the impact of excess parathyroid hormone (PTH) on calcium metabolism. Referencing putative neurocognitive issues, many animal studies have illustrated the potential roles of PTH and PTH receptors in the brain. Functional imaging and pre-and post-parathyroidectomy studies have suggested a link between the neuronal impact of elevated PTH levels on specific functional aspects of the central nervous system, such as cognition. Confounding a direct role for PTH are hypercalcemia and vitamin D deficiency, both of which could conceivably alter CNS function in PHPT. The lack of strong evidence that parathyroidectomy improves cognition in patients with PHPT raises the question as to whether parathyroid surgery should be recommended on this basis alone. This narrative review summarizes the available literature on neurocognitive function in PHPT.
Literature
1.
go back to reference Lundgren E, Hagström EG, Lundin J, et al. Primary hyperparathyroidism revisited in menopausal women with serum calcium in the upper normal range at population-based screening 8 years ago. World J Surg. 2002;26(8):931–6.PubMedCrossRef Lundgren E, Hagström EG, Lundin J, et al. Primary hyperparathyroidism revisited in menopausal women with serum calcium in the upper normal range at population-based screening 8 years ago. World J Surg. 2002;26(8):931–6.PubMedCrossRef
3.
go back to reference Albright F, Reifenstein E Jr. The parathyroid glands and metabolic bone disease. selected studies. Fuller Albright, A.B., M.D., and Edward C. Reifenstein, Jr., A.B., M.D., F.A.C.P. Baltimore, The Williams and Wilkins Company, 1948. $8.00. JBJS 1949; 31(4). Albright F, Reifenstein E Jr. The parathyroid glands and metabolic bone disease. selected studies. Fuller Albright, A.B., M.D., and Edward C. Reifenstein, Jr., A.B., M.D., F.A.C.P. Baltimore, The Williams and Wilkins Company, 1948. $8.00. JBJS 1949; 31(4).
4.
go back to reference Minisola S, Gianotti L, Bhadada S, Silverberg SJ. Classical complications of primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab. 2018;32(6):791–803.PubMedCrossRef Minisola S, Gianotti L, Bhadada S, Silverberg SJ. Classical complications of primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab. 2018;32(6):791–803.PubMedCrossRef
5.
go back to reference Chiodini I, Cairoli E, Palmieri S, Pepe J, Walker MD. Non classical complications of primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab. 2018;32(6):805–20.PubMedCrossRef Chiodini I, Cairoli E, Palmieri S, Pepe J, Walker MD. Non classical complications of primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab. 2018;32(6):805–20.PubMedCrossRef
7.
8.
9.
go back to reference Alex G, Morris L, Pasieka J, Perrier N. Nonclassical symptoms of primary hyperparathyroidism and their response to parathyroidectomy. Am Surg. 2013;79(4):337–43.PubMedCrossRef Alex G, Morris L, Pasieka J, Perrier N. Nonclassical symptoms of primary hyperparathyroidism and their response to parathyroidectomy. Am Surg. 2013;79(4):337–43.PubMedCrossRef
11.
go back to reference Gardella TJ, J-P Vilardaga. International union of basic and clinical pharmacology. XCIII. The parathyroid hormone receptors-family B G protein-coupled receptors. Pharmacol Rev. 2015;67(2):310–37.PubMedPubMedCentralCrossRef Gardella TJ, J-P Vilardaga. International union of basic and clinical pharmacology. XCIII. The parathyroid hormone receptors-family B G protein-coupled receptors. Pharmacol Rev. 2015;67(2):310–37.PubMedPubMedCentralCrossRef
13.
go back to reference Gensure RC, Gardella TJ, Jüppner H. Parathyroid hormone and parathyroid hormone-related peptide, and their receptors. Biochem Biophys Res Commun. 2005;328(3):666–78.PubMedCrossRef Gensure RC, Gardella TJ, Jüppner H. Parathyroid hormone and parathyroid hormone-related peptide, and their receptors. Biochem Biophys Res Commun. 2005;328(3):666–78.PubMedCrossRef
14.
go back to reference Nemeth EF, Scarpa A. Rapid mobilization of cellular Ca2+ in bovine parathyroid cells evoked by extracellular divalent cations. Evidence for a cell surface calcium receptor. J Biol Chem. 1987;262(11):5188–96.PubMedCrossRef Nemeth EF, Scarpa A. Rapid mobilization of cellular Ca2+ in bovine parathyroid cells evoked by extracellular divalent cations. Evidence for a cell surface calcium receptor. J Biol Chem. 1987;262(11):5188–96.PubMedCrossRef
15.
go back to reference Conigrave AD. The calcium-sensing receptor and the parathyroid: past, present, future. Front Physiol. 2016;7. Conigrave AD. The calcium-sensing receptor and the parathyroid: past, present, future. Front Physiol. 2016;7.
16.
go back to reference Tfelt-Hansen J, Brown EM. The calcium-sensing receptor in normal physiology and pathophysiology: a review. Crit Rev Clin Lab Sci. 2005;42(1):35–70.PubMedCrossRef Tfelt-Hansen J, Brown EM. The calcium-sensing receptor in normal physiology and pathophysiology: a review. Crit Rev Clin Lab Sci. 2005;42(1):35–70.PubMedCrossRef
17.
go back to reference Chou YH, Pollak MR, Brandi ML, et al. Mutations in the human Ca(2+)-sensing-receptor gene that cause familial hypocalciuric hypercalcemia. Am J Hum Genet. 1995;56(5):1075–9.PubMedPubMedCentral Chou YH, Pollak MR, Brandi ML, et al. Mutations in the human Ca(2+)-sensing-receptor gene that cause familial hypocalciuric hypercalcemia. Am J Hum Genet. 1995;56(5):1075–9.PubMedPubMedCentral
18.
go back to reference Pollak MR, Brown EM, Chou YH, et al. Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell. 1993;75(7):1297–303.PubMedCrossRef Pollak MR, Brown EM, Chou YH, et al. Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell. 1993;75(7):1297–303.PubMedCrossRef
19.
go back to reference Pollak MR, Brown EM, Estep HL, et al. Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing receptor gene mutation. Nat Genet. 1994;8(3):303–7.PubMedCrossRef Pollak MR, Brown EM, Estep HL, et al. Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing receptor gene mutation. Nat Genet. 1994;8(3):303–7.PubMedCrossRef
20.
go back to reference Taylor CW, Tovey SC. From parathyroid hormone to cytosolic Ca2+ signals. Biochem Soc Trans. 2012;40(1):147–52.PubMedCrossRef Taylor CW, Tovey SC. From parathyroid hormone to cytosolic Ca2+ signals. Biochem Soc Trans. 2012;40(1):147–52.PubMedCrossRef
21.
go back to reference Usdin TB, Dobolyi A, Ueda H, Palkovits M. Emerging functions for tuberoinfundibular peptide of 39 residues. Trends Endocrinol Metab. 2003;14(1):14–9.PubMedCrossRef Usdin TB, Dobolyi A, Ueda H, Palkovits M. Emerging functions for tuberoinfundibular peptide of 39 residues. Trends Endocrinol Metab. 2003;14(1):14–9.PubMedCrossRef
22.
23.
go back to reference Dobolyi A, Dimitrov E, Palkovits M, Usdin TB. The neuroendocrine functions of the parathyroid hormone 2 receptor. Front Endocrinol (Lausanne). 2012;3:121-. Dobolyi A, Dimitrov E, Palkovits M, Usdin TB. The neuroendocrine functions of the parathyroid hormone 2 receptor. Front Endocrinol (Lausanne). 2012;3:121-.
24.
go back to reference Usdin TB, Hoare SR, Wang T, Mezey E, Kowalak JA. TIP39: a new neuropeptide and PTH2-receptor agonist from hypothalamus. Nat Neurosci. 1999;2(11):941–3.PubMedCrossRef Usdin TB, Hoare SR, Wang T, Mezey E, Kowalak JA. TIP39: a new neuropeptide and PTH2-receptor agonist from hypothalamus. Nat Neurosci. 1999;2(11):941–3.PubMedCrossRef
25.
go back to reference Dobolyi A, Ueda H, Uchida H, Palkovits M, Usdin TB. Anatomical and physiological evidence for involvement of tuberoinfundibular peptide of 39 residues in nociception. Proc Natl Acad Sci U S A. 2002;99(3):1651–6.PubMedPubMedCentralCrossRef Dobolyi A, Ueda H, Uchida H, Palkovits M, Usdin TB. Anatomical and physiological evidence for involvement of tuberoinfundibular peptide of 39 residues in nociception. Proc Natl Acad Sci U S A. 2002;99(3):1651–6.PubMedPubMedCentralCrossRef
26.
go back to reference Dobolyi A, Palkovits M, Usdin TB. The TIP39-PTH2 receptor system: unique peptidergic cell groups in the brainstem and their interactions with central regulatory mechanisms. Prog Neurobiol. 2010;90(1):29–59.PubMedCrossRef Dobolyi A, Palkovits M, Usdin TB. The TIP39-PTH2 receptor system: unique peptidergic cell groups in the brainstem and their interactions with central regulatory mechanisms. Prog Neurobiol. 2010;90(1):29–59.PubMedCrossRef
27.
go back to reference Coutellier L, Logemann A, Kuo J, Rusnak M, Usdin TB. TIP39 modulates effects of novelty-induced arousal on memory. Genes Brain Behav. 2011;10(1):90–9.PubMedCrossRef Coutellier L, Logemann A, Kuo J, Rusnak M, Usdin TB. TIP39 modulates effects of novelty-induced arousal on memory. Genes Brain Behav. 2011;10(1):90–9.PubMedCrossRef
28.
go back to reference Venkatesh G, Sankar V, Ramanathan M. Molecular mechanism of tuberoinfundibular peptide of 39 on glucocorticoid receptor mediated glutamate/GABA imbalance and cerebral abnormalities against cognitive deficit model. J Pharm Pharmacol. 2019;71(6):996–1006.PubMedCrossRef Venkatesh G, Sankar V, Ramanathan M. Molecular mechanism of tuberoinfundibular peptide of 39 on glucocorticoid receptor mediated glutamate/GABA imbalance and cerebral abnormalities against cognitive deficit model. J Pharm Pharmacol. 2019;71(6):996–1006.PubMedCrossRef
29.
go back to reference Faber CA, Dobolyi A, Sleeman M, Usdin TB. Distribution of tuberoinfundibular peptide of 39 residues and its receptor, parathyroid hormone 2 receptor, in the mouse brain. J Comp Neurol. 2007;502(4):563–83.PubMedPubMedCentralCrossRef Faber CA, Dobolyi A, Sleeman M, Usdin TB. Distribution of tuberoinfundibular peptide of 39 residues and its receptor, parathyroid hormone 2 receptor, in the mouse brain. J Comp Neurol. 2007;502(4):563–83.PubMedPubMedCentralCrossRef
30.
go back to reference de Kloet ER. Hormones, brain and stress. Endocr Regul. 2003;37(2):51–68.PubMed de Kloet ER. Hormones, brain and stress. Endocr Regul. 2003;37(2):51–68.PubMed
31.
go back to reference Alkadhi K. Brain Physiology and Pathophysiology in Mental Stress. ISRN Physiology. 2013;2013: 806104.CrossRef Alkadhi K. Brain Physiology and Pathophysiology in Mental Stress. ISRN Physiology. 2013;2013: 806104.CrossRef
32.
go back to reference Henckens MJ, van Wingen GA, Joëls M, Fernández G. Time-dependent corticosteroid modulation of prefrontal working memory processing. Proc Natl Acad Sci U S A. 2011;108(14):5801–6.PubMedPubMedCentralCrossRef Henckens MJ, van Wingen GA, Joëls M, Fernández G. Time-dependent corticosteroid modulation of prefrontal working memory processing. Proc Natl Acad Sci U S A. 2011;108(14):5801–6.PubMedPubMedCentralCrossRef
33.
go back to reference Veintramuthu S, Gunasekaran V, Ramanathan M, Selvaraj D. Tuberoinfundibular peptide of 39 attenuates chronic unpredictable mild stress induced HPA axis dysregulation, inflammation and oxidative damage in depressive rats. Curr Bioact Compd. 2018;14(4):451–60.CrossRef Veintramuthu S, Gunasekaran V, Ramanathan M, Selvaraj D. Tuberoinfundibular peptide of 39 attenuates chronic unpredictable mild stress induced HPA axis dysregulation, inflammation and oxidative damage in depressive rats. Curr Bioact Compd. 2018;14(4):451–60.CrossRef
34.
go back to reference Gunasekaran V, Mathew MM, Gautam M, Ramanathan M. Neuroprotective role of Pterocarpus marsupium Roxb in streptozotocin-induced diabetic neuropathic pain in Type 2 diabetic rats. J Pharm Res. 2017;11:1–7. Gunasekaran V, Mathew MM, Gautam M, Ramanathan M. Neuroprotective role of Pterocarpus marsupium Roxb in streptozotocin-induced diabetic neuropathic pain in Type 2 diabetic rats. J Pharm Res. 2017;11:1–7.
35.
go back to reference Usdin TB, Gruber C, Bonner TI. Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor. J Biol Chem. 1995;270(26):15455–8.PubMedCrossRef Usdin TB, Gruber C, Bonner TI. Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor. J Biol Chem. 1995;270(26):15455–8.PubMedCrossRef
36.
37.
go back to reference Cermik TF, Kaya M, Uğur-Altun B, Bedel D, Berkarda S, Yiğitbaşi ON. Regional cerebral blood flow abnormalities in patients with primary hyperparathyroidism. Neuroradiology. 2007;49(4):379–85.PubMedCrossRef Cermik TF, Kaya M, Uğur-Altun B, Bedel D, Berkarda S, Yiğitbaşi ON. Regional cerebral blood flow abnormalities in patients with primary hyperparathyroidism. Neuroradiology. 2007;49(4):379–85.PubMedCrossRef
38.
go back to reference Walker MD, Fleischer J, Rundek T, et al. Carotid vascular abnormalities in primary hyperparathyroidism. J Clin Endocrinol Metab. 2009;94(10):3849–56.PubMedPubMedCentralCrossRef Walker MD, Fleischer J, Rundek T, et al. Carotid vascular abnormalities in primary hyperparathyroidism. J Clin Endocrinol Metab. 2009;94(10):3849–56.PubMedPubMedCentralCrossRef
39.
go back to reference Khudaverdyan DN, Asratyan AA. Effect of the parathyroid hormone—Calcium system on functional activity of the hypothalamus-neurohypophysis complex. Bull Exp Biol Med. 1996;122(5):1069–71.CrossRef Khudaverdyan DN, Asratyan AA. Effect of the parathyroid hormone—Calcium system on functional activity of the hypothalamus-neurohypophysis complex. Bull Exp Biol Med. 1996;122(5):1069–71.CrossRef
40.
go back to reference Cope O. The story of hyperparathyroidism at the Massachusetts General Hospital. N Engl J Med. 1966;274(21):1174–82.PubMedCrossRef Cope O. The story of hyperparathyroidism at the Massachusetts General Hospital. N Engl J Med. 1966;274(21):1174–82.PubMedCrossRef
41.
go back to reference Albright F, Aub JC, Bauer W. Hyperparathyroidism: a common and polymorphic condition as illustrated by seventeen proved cases from one clinic. J Am Med Assoc. 1934;102(16):1276–87.CrossRef Albright F, Aub JC, Bauer W. Hyperparathyroidism: a common and polymorphic condition as illustrated by seventeen proved cases from one clinic. J Am Med Assoc. 1934;102(16):1276–87.CrossRef
42.
go back to reference Silverberg SJ. Non-classical target organs in primary hyperparathyroidism. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 2002;17:N117–25. Silverberg SJ. Non-classical target organs in primary hyperparathyroidism. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 2002;17:N117–25.
43.
go back to reference Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009;94(2):351–65.PubMedPubMedCentralCrossRef Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009;94(2):351–65.PubMedPubMedCentralCrossRef
44.
go back to reference Wilhelm SM, Wang TS, Ruan DT, et al. The American Association of Endocrine Surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg. 2016;151(10):959–68.PubMedCrossRef Wilhelm SM, Wang TS, Ruan DT, et al. The American Association of Endocrine Surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg. 2016;151(10):959–68.PubMedCrossRef
46.
go back to reference Chiang CY, Andrewes DG, Anderson D, Devere M, Schweitzer I, Zajac JD. A controlled, prospective study of neuropsychological outcomes post parathyroidectomy in primary hyperparathyroid patients. Clin Endocrinol (Oxf). 2005;62(1):99–104.CrossRef Chiang CY, Andrewes DG, Anderson D, Devere M, Schweitzer I, Zajac JD. A controlled, prospective study of neuropsychological outcomes post parathyroidectomy in primary hyperparathyroid patients. Clin Endocrinol (Oxf). 2005;62(1):99–104.CrossRef
47.
go back to reference Roman SA, Sosa JA, Mayes L, et al. Parathyroidectomy improves neurocognitive deficits in patients with primary hyperparathyroidism. Surgery. 2005;138(6):1121–8; discussion 8–9 Roman SA, Sosa JA, Mayes L, et al. Parathyroidectomy improves neurocognitive deficits in patients with primary hyperparathyroidism. Surgery. 2005;138(6):1121–8; discussion 8–9
48.
go back to reference Benge JF, Perrier ND, Massman PJ, Meyers CA, Kayl AE, Wefel JS. Cognitive and affective sequelae of primary hyperparathyroidism and early response to parathyroidectomy. J Int Neuropsychol Soc. 2009;15(6):1002–11.PubMedCrossRef Benge JF, Perrier ND, Massman PJ, Meyers CA, Kayl AE, Wefel JS. Cognitive and affective sequelae of primary hyperparathyroidism and early response to parathyroidectomy. J Int Neuropsychol Soc. 2009;15(6):1002–11.PubMedCrossRef
49.
go back to reference Perrier ND, Balachandran D, Wefel JS, et al. Prospective, randomized, controlled trial of parathyroidectomy versus observation in patients with “asymptomatic” primary hyperparathyroidism. Surgery. 2009;146(6):1116–22.PubMedCrossRef Perrier ND, Balachandran D, Wefel JS, et al. Prospective, randomized, controlled trial of parathyroidectomy versus observation in patients with “asymptomatic” primary hyperparathyroidism. Surgery. 2009;146(6):1116–22.PubMedCrossRef
50.
go back to reference Dotzenrath CM, Kaetsch AK, Pfingsten H, et al. Neuropsychiatric and cognitive changes after surgery for primary hyperparathyroidism. World J Surg. 2006;30(5):680–5.PubMedCrossRef Dotzenrath CM, Kaetsch AK, Pfingsten H, et al. Neuropsychiatric and cognitive changes after surgery for primary hyperparathyroidism. World J Surg. 2006;30(5):680–5.PubMedCrossRef
51.
go back to reference Numann P, Torppa A, Blumetti A. Neuropsychologic deficits associated with primary hyperparathyroidism. Surgery. 1984;96(6):1119–23.PubMed Numann P, Torppa A, Blumetti A. Neuropsychologic deficits associated with primary hyperparathyroidism. Surgery. 1984;96(6):1119–23.PubMed
52.
go back to reference Babińska D, Barczyński M, Stefaniak T, et al. Evaluation of selected cognitive functions before and after surgery for primary hyperparathyroidism. Langenbecks Arch Surg. 2012;397(5):825–31.PubMedCrossRef Babińska D, Barczyński M, Stefaniak T, et al. Evaluation of selected cognitive functions before and after surgery for primary hyperparathyroidism. Langenbecks Arch Surg. 2012;397(5):825–31.PubMedCrossRef
53.
go back to reference Casella C, Pata G, Di Betta E, Nascimbeni R. Neurological and psychiatric disorders in primary hyperparathyroidism: the role of parathyroidectomy. Annali Italiani Di Chirurgia 2008;79(3):157–61; discussion 61. Casella C, Pata G, Di Betta E, Nascimbeni R. Neurological and psychiatric disorders in primary hyperparathyroidism: the role of parathyroidectomy. Annali Italiani Di Chirurgia 2008;79(3):157–61; discussion 61.
54.
go back to reference Mittendorf EA, Wefel JS, Meyers CA, et al. Improvement of sleep disturbance and neurocognitive function after parathyroidectomy in patients with primary hyperparathyroidism. Endocr Pract. 2007;13(4):338–44.PubMedCrossRef Mittendorf EA, Wefel JS, Meyers CA, et al. Improvement of sleep disturbance and neurocognitive function after parathyroidectomy in patients with primary hyperparathyroidism. Endocr Pract. 2007;13(4):338–44.PubMedCrossRef
55.
go back to reference Prager G, Kalaschek A, Kaczirek K, et al. Parathyroidectomy improves concentration and retentiveness in patients with primary hyperparathyroidism. Surgery. 2002;132(6):930–6.PubMedCrossRef Prager G, Kalaschek A, Kaczirek K, et al. Parathyroidectomy improves concentration and retentiveness in patients with primary hyperparathyroidism. Surgery. 2002;132(6):930–6.PubMedCrossRef
56.
go back to reference Roman SA, Sosa JA, Pietrzak RH, et al. The effects of serum calcium and parathyroid hormone changes on psychological and cognitive function in patients undergoing parathyroidectomy for primary hyperparathyroidism. Ann Surg. 2011;253(1):131–7.PubMedCrossRef Roman SA, Sosa JA, Pietrzak RH, et al. The effects of serum calcium and parathyroid hormone changes on psychological and cognitive function in patients undergoing parathyroidectomy for primary hyperparathyroidism. Ann Surg. 2011;253(1):131–7.PubMedCrossRef
57.
go back to reference Walker MD, McMahon DJ, Inabnet WB, et al. Neuropsychological features in primary hyperparathyroidism: a prospective study. J Clin Endocrinol Metab. 2009;94(6):1951–8.PubMedPubMedCentralCrossRef Walker MD, McMahon DJ, Inabnet WB, et al. Neuropsychological features in primary hyperparathyroidism: a prospective study. J Clin Endocrinol Metab. 2009;94(6):1951–8.PubMedPubMedCentralCrossRef
58.
go back to reference Cogan MG, Covey CM, Arieff AI, et al. Central nervous system manifestations of hyperparathyroidism. Am J Med. 1978;65(6):963–70.PubMedCrossRef Cogan MG, Covey CM, Arieff AI, et al. Central nervous system manifestations of hyperparathyroidism. Am J Med. 1978;65(6):963–70.PubMedCrossRef
59.
go back to reference Goyal A, Chumber S, Tandon N, Lal R, Srivastava A, Gupta S. Neuropsychiatric manifestations in patients of primary hyperparathyroidism and outcome following surgery. Indian J Med Sci. 2001;55(12):677–86.PubMed Goyal A, Chumber S, Tandon N, Lal R, Srivastava A, Gupta S. Neuropsychiatric manifestations in patients of primary hyperparathyroidism and outcome following surgery. Indian J Med Sci. 2001;55(12):677–86.PubMed
60.
go back to reference Liu M, Sum M, Cong E, et al. Cognition and cerebrovascular function in primary hyperparathyroidism before and after parathyroidectomy. J Endocrinol Invest. 2020;43(3):369–79.PubMedCrossRef Liu M, Sum M, Cong E, et al. Cognition and cerebrovascular function in primary hyperparathyroidism before and after parathyroidectomy. J Endocrinol Invest. 2020;43(3):369–79.PubMedCrossRef
61.
go back to reference Zanocco K, Butt Z, Kaltman D, et al. Improvement in patient-reported physical and mental health after parathyroidectomy for primary hyperparathyroidism. Surgery. 2015;158(3):837–45.PubMedCrossRef Zanocco K, Butt Z, Kaltman D, et al. Improvement in patient-reported physical and mental health after parathyroidectomy for primary hyperparathyroidism. Surgery. 2015;158(3):837–45.PubMedCrossRef
62.
go back to reference Lourida I, Thompson-Coon J, Dickens CM, et al. Parathyroid hormone, cognitive function and dementia: a systematic review. PLoS ONE. 2015;10(5): e0127574.PubMedPubMedCentralCrossRef Lourida I, Thompson-Coon J, Dickens CM, et al. Parathyroid hormone, cognitive function and dementia: a systematic review. PLoS ONE. 2015;10(5): e0127574.PubMedPubMedCentralCrossRef
63.
go back to reference Pretorius M, Lundstam K, Hellström M, et al. Effects of parathyroidectomy on quality of life: 10 years of data from a prospective randomized controlled trial on primary hyperparathyroidism (the SIPH-Study). J Bone Miner Res. 2021;36(1):3–11.PubMedCrossRef Pretorius M, Lundstam K, Hellström M, et al. Effects of parathyroidectomy on quality of life: 10 years of data from a prospective randomized controlled trial on primary hyperparathyroidism (the SIPH-Study). J Bone Miner Res. 2021;36(1):3–11.PubMedCrossRef
64.
go back to reference Sheldon DG, Lee FT, Neil NJ, Ryan JA Jr. Surgical treatment of hyperparathyroidism improves health-related quality of life. Arch Surg. 2002;137(9):1022–6; discussion 6–8. Sheldon DG, Lee FT, Neil NJ, Ryan JA Jr. Surgical treatment of hyperparathyroidism improves health-related quality of life. Arch Surg. 2002;137(9):1022–6; discussion 6–8.
65.
go back to reference Caillard C, Sebag F, Mathonnet M, et al. Prospective evaluation of quality of life (SF-36v2) and nonspecific symptoms before and after cure of primary hyperparathyroidism (1-year follow-up). Surgery. 2007;141(2):153–9; discussion 9–60. Caillard C, Sebag F, Mathonnet M, et al. Prospective evaluation of quality of life (SF-36v2) and nonspecific symptoms before and after cure of primary hyperparathyroidism (1-year follow-up). Surgery. 2007;141(2):153–9; discussion 9–60.
66.
go back to reference Ambrogini E, Cetani F, Cianferotti L, et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab. 2007;92(8):3114–21.PubMedCrossRef Ambrogini E, Cetani F, Cianferotti L, et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab. 2007;92(8):3114–21.PubMedCrossRef
67.
go back to reference Mihai R, Sadler GP. Pasieka’s parathyroid symptoms scores correlate with SF-36 scores in patients undergoing surgery for primary hyperparathyroidism. World J Surg. 2008;32(5):807–14.PubMedCrossRef Mihai R, Sadler GP. Pasieka’s parathyroid symptoms scores correlate with SF-36 scores in patients undergoing surgery for primary hyperparathyroidism. World J Surg. 2008;32(5):807–14.PubMedCrossRef
68.
go back to reference Bollerslev J, Jansson S, Mollerup CL, et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab. 2007;92(5):1687–92.PubMedCrossRef Bollerslev J, Jansson S, Mollerup CL, et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab. 2007;92(5):1687–92.PubMedCrossRef
69.
go back to reference Kowdley KV, Coull BM, Orwoll ES. Cognitive impairment and intracranial calcification in chronic hypoparathyroidism. Am J Med Sci. 1999;317(5):273–7.PubMedCrossRef Kowdley KV, Coull BM, Orwoll ES. Cognitive impairment and intracranial calcification in chronic hypoparathyroidism. Am J Med Sci. 1999;317(5):273–7.PubMedCrossRef
70.
71.
go back to reference Llewellyn DJ, Lang IA, Langa KM, Melzer D. Vitamin D and cognitive impairment in the elderly U.S. population. J Gerontol A Biol Sci Med Sci. 2011;66(1):59–65.PubMedCrossRef Llewellyn DJ, Lang IA, Langa KM, Melzer D. Vitamin D and cognitive impairment in the elderly U.S. population. J Gerontol A Biol Sci Med Sci. 2011;66(1):59–65.PubMedCrossRef
72.
go back to reference Giustina A, Bouillon R, Binkley N, et al. Controversies in Vitamin D: A statement from the third international conference. JBMR Plus. 2020;4(12):e10417-n/a. Giustina A, Bouillon R, Binkley N, et al. Controversies in Vitamin D: A statement from the third international conference. JBMR Plus. 2020;4(12):e10417-n/a.
73.
go back to reference Michos ED, Carson KA, Schneider AL, et al. Vitamin D and subclinical cerebrovascular disease: the Atherosclerosis Risk in Communities brain magnetic resonance imaging study. JAMA Neurol. 2014;71(7):863–71.PubMedPubMedCentralCrossRef Michos ED, Carson KA, Schneider AL, et al. Vitamin D and subclinical cerebrovascular disease: the Atherosclerosis Risk in Communities brain magnetic resonance imaging study. JAMA Neurol. 2014;71(7):863–71.PubMedPubMedCentralCrossRef
74.
go back to reference Moon JH, Lim S, Han JW, et al. Serum 25-hydroxyvitamin D level and the risk of mild cognitive impairment and dementia: the Korean Longitudinal Study on Health and Aging (KLoSHA). Clin Endocrinol (Oxf). 2015;83(1):36–42.CrossRef Moon JH, Lim S, Han JW, et al. Serum 25-hydroxyvitamin D level and the risk of mild cognitive impairment and dementia: the Korean Longitudinal Study on Health and Aging (KLoSHA). Clin Endocrinol (Oxf). 2015;83(1):36–42.CrossRef
75.
76.
go back to reference Silverberg SJ. Vitamin D deficiency and primary hyperparathyroidism. J Bone Miner Res. 2007;22(Suppl 2):V100–4.PubMedCrossRef Silverberg SJ. Vitamin D deficiency and primary hyperparathyroidism. J Bone Miner Res. 2007;22(Suppl 2):V100–4.PubMedCrossRef
77.
go back to reference Crosson B, Ford A, McGregor KM, et al. Functional imaging and related techniques: an introduction for rehabilitation researchers. J Rehabil Res Dev. 2010;47(2):vii-xxxiv. Crosson B, Ford A, McGregor KM, et al. Functional imaging and related techniques: an introduction for rehabilitation researchers. J Rehabil Res Dev. 2010;47(2):vii-xxxiv.
79.
go back to reference Perrier ND, Coker LH, Rorie KD, et al. Preliminary report: functional MRI of the brain may be the ideal tool for evaluating neuropsychologic and sleep complaints of patients with primary hyperparathyroidism. World J Surg. 2006;30(5):686–96.PubMedCrossRef Perrier ND, Coker LH, Rorie KD, et al. Preliminary report: functional MRI of the brain may be the ideal tool for evaluating neuropsychologic and sleep complaints of patients with primary hyperparathyroidism. World J Surg. 2006;30(5):686–96.PubMedCrossRef
80.
go back to reference Çermik TF, Kaya M, Uğur-Altun B, Bedel D, Berkarda Ş, Yiğitbaşı ÖN. Regional cerebral blood flow abnormalities in patients with primary hyperparathyroidism. Neuroradiology. 2007;49(4):379–85.PubMedCrossRef Çermik TF, Kaya M, Uğur-Altun B, Bedel D, Berkarda Ş, Yiğitbaşı ÖN. Regional cerebral blood flow abnormalities in patients with primary hyperparathyroidism. Neuroradiology. 2007;49(4):379–85.PubMedCrossRef
81.
82.
go back to reference Chen SHA, Wu C-Y, Lua R-p, Akoshi MM, Nakai T. Age-related changes in resting-state and task-activated functional MRI networks. IEEE. 2013;218–22. Chen SHA, Wu C-Y, Lua R-p, Akoshi MM, Nakai T. Age-related changes in resting-state and task-activated functional MRI networks. IEEE. 2013;218–22.
83.
go back to reference Lou Y, Zhao L, Yu S, et al. Brain asymmetry differences between Chinese and Caucasian populations: a surface-based morphometric comparison study. Brain Imaging Behav. 2019;14(6):2323–32.CrossRef Lou Y, Zhao L, Yu S, et al. Brain asymmetry differences between Chinese and Caucasian populations: a surface-based morphometric comparison study. Brain Imaging Behav. 2019;14(6):2323–32.CrossRef
Metadata
Title
Cognitive deficits in primary hyperparathyroidism – what we know and what we do not know: A narrative review
Authors
Manju Chandran
Lydia Tan Li Yeh
Mechteld C. de Jong
John P. Bilezikian
Rajeev Parameswaran
Publication date
22-08-2022
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 5/2022
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-022-09750-9

Other articles of this Issue 5/2022

Reviews in Endocrine and Metabolic Disorders 5/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine